Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- IFNβ IFNβ anti viral proliferative SARSCoV SARSCoV2 CoV2 COVID19 Huh 7 Met 22 IFF IFB IFNB 1
- Product Overview:
Interferon-β (IFN-β) is a cytokine and type I IFN with roles in antiviral responses and regulation of innate and adaptive immunity.{56197} It is produced mainly by fibroblasts in response to viral pathogens, which are detected by a diverse repertoire of pathogen recognition receptors (PRRs).{56197,56198} IFN-β binds to the IFN-α/β receptor (IFNAR) and induces signal transduction through the canonical JAK/STAT signaling pathway to induce the expression of IFN-stimulated genes (ISGs), which encode proteins that have antiviral, antiproliferative, or immunomodulatory properties, leading to the induction of an antiviral state in infected and neighboring cells and inhibiting viral replication.{56197} IFN-β inhibits the replication of a variety of viral pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, and induces cell cycle arrest at the S phase and apoptosis in Huh7 hepatocellular carcinoma cells in vitro.{56199,56200} Formulations containing IFN-β have been used in the treatment of multiple sclerosis. Cayman’s IFN-β (human, recombinant) protein can be used for cell-based assays. This protein consists of 166 amino acids, has a calculated molecular weight of 20 kDa, and a predicted N-terminus of Met22 after signal peptide cleavage.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.